Hyatt Regency Huntington Beach Resort and Spa
Grand Ballroom
21500 Pacific Coast Highway
Huntington Beach, California, 92648
Rheumatologists, dermatologists, NPs and PAs who help manage patients with psoriatic arthritis
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 0.57 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.75 CPE Contact Hours (0.075 CEUs) of Continuing Pharmacy Education Credit (UAN# JA4008190-0000-26-011-L01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Bristol-Myers Squibb Company.
Hyatt Regency Huntington Beach Resort and Spa
Grand Ballroom
21500 Pacific Coast Highway
Huntington Beach, California, 92648
For all CE inquiries or special needs, please contact admin@academiccme.com.
Review the current pathophysiology and therapeutic targets for PsA, modes of action of current and emerging oral therapies, and unmet patient needs in the management of PsA
Analyze the most up to date clinical trial data for current and emerging oral treatments, including TYK2 blockers for patients with PsA
Discuss the potential patient selection and clinical applications for newer oral therapies in PsA, including patient preferences, tolerability of side effects, and comorbidities
|
I. Update on Psoriatic Arthritis
a.Review of Immunopathology and Therapeutic Targets
b.The Mechanism of Action of TYK2 Inhibitors
c.Current Approved Oral Therapies
d.Unmet Patient Needs and Comorbidity Concerns
|
|
II. Efficacy and Safety of Current and Emerging Oral Therapies
a.TYK2 Inhibitors
b.Reductions in Associated Comorbidities
c.Potential Applications and Considerations When Individualizing Treatments
|
|
III. The Evolving Role of Newer Oral Therapies for PsA
a.Adherence to Treatment
b.Optimizing Quality of Life
|
|
I. Update on Psoriatic Arthritis
a.Review of Immunopathology and Therapeutic Targets
b.The Mechanism of Action of TYK2 Inhibitors
c.Current Approved Oral Therapies
d.Unmet Patient Needs and Comorbidity Concerns
|
|
II. Efficacy and Safety of Current and Emerging Oral Therapies
a.TYK2 Inhibitors
b.Reductions in Associated Comorbidities
c.Potential Applications and Considerations When Individualizing Treatments
|
|
III. The Evolving Role of Newer Oral Therapies for PsA
a.Adherence to Treatment
b.Optimizing Quality of Life
|